Clinical Trials
We develop new tools for diagnosing and treating cancer. The CRUK Clinical Trials Unit works together with clinicians to take advances in medicine and surgery forward to the clinic. We translate cutting edge science into improved patient care through the design of large multi-centre/international randomised trials as well as more data intensive Phase I trials of novel therapies.
Theme Lead
Research groups
Haematology and Oncology
| Researcher | Research area |
|---|
|
Myeloid malignancies |
Spotlight on COVID-19 vaccination and outcomes in immuno-suppressed patients
Nature Medicine doi.org/10.1038/s41591-023-02414-4 (2023). Eleanor Barnes, Carl S. Goodyear, Michelle Willicombe, Charlotte Gaskell, Stefan Siebert, Thushan I de Silva, Sam M. Murray, Daniel Rea, John A. Snowden, Miles Carroll, Sarah Pirrie, Sarah J. Bowden, Susanna J. Dunachie, Alex Richter, Zixiang Lim, Jack Satsangi, Gordon Cook, Ann Pope, Ana Hughes, Molly Harrison, Sean H. Lim, Paul Miller, Paul Klenerman, PITCH consortium, Neil Basu, Ashley Gilmour, Sophie Irwin, Georgina Meacham, Thomas Marjot, Stavros Dimitriadis, Peter Kelleher, Maria Prendecki, Candice Clarke, Paige Mortimer, Stacey McIntyre, Rachael Selby, Naomi Meardon, Dung Nguyen, Tom Tipton, Stephanie Longet, Stephen Laidlaw, Kim Orchard, Georgina Ireland, David Thomas, Pamela Kearns, Amanda Kirkham, Iain B. McInnes and The OCTAVE Collaborative Group. .
This study from the OCTAVE trial followed up on the outcomes of immuno-suppressed patients following COVID-19 vaccination. This ongoing trial is a collaboration between CRUK Clinical Trial Unit, led by Professor Pam Kearns, and the Universities of Glasgow and Oxford, and a consortium of other leading UK institutions. It reports on data from 20 hospital sites across the UK who enrolled 2686 patients with reduced function of their immune systems.
This new publication from the OCTAVE trial shows, for the first time, the real-world vaccine responses and infection outcomes in clinically at-risk patients with a range of immunocompromised or immunosuppressed conditions. Overall, it found that 12% patients failed to develop anti-spike antibodies, and 17% of patients became ill with COVID-19 up to one year after the date of their first vaccination. Most infections (90%) were mild in severity, including some asymptomatic cases. Severe cases requiring hospitalisation or death was reported in 9.8% of infections and occurred predominantly in patients with renal disease.
583:807-812 (2020). Middleton G, P Fletcher, S Popat, J Savage, Y Summers, A Greystoke, . . .and L Billingham. .
A pioneering lung cancer study, led by the University 麻豆精选’s Cancer Research UK Clinical Trials Unit, has highlighted important factors that will need to be considered in the next wave of precision medicine studies particularly in treating genomically complicated cancers.
The National Lung Matrix Trial (NLMT) is the world’s largest precision medicine clinical trial for non-small-cell lung cancer (NSCLC) patients.
Selected highlights from this research theme
Nature Medicine doi.org/10.1038/s41591-023-02414-4 (2023). Barnes E, CS Goodyear, M Willicombe, C Gaskell, . . . . . . Thomas D, Kearns P, Kirkham A, McInnes IB, and The OCTAVE Collaborative Group. .
BMJ 376:e068177 (2022). Homer V, C Yap, S Bond, J Holmes, D Stocken, K Walker, . . . P Gaunt. .
J Clin Oncol JCO2200033 (2022). De Wilde B, E Barry, E Fox, D Karres, M Kieran, J Manlay, . . . P Kearns.
Arch Dis Child 107:186-188 (2022). Millen GC, R Arnold, JB Cazier, H Curley, R Feltbower, A Gamble, . . . P Kearns. C.
British J Cancer 124:754-759 (2021). Millen GC, R Arnold, JB Cazier, H Curley, RG Feltbower, A Gamble, . . . C Varnai, PR Kearns. .
iScience 24:103215 (2021). Syrimi E, E Fennell, A Richter, P Vrljicak, R Stark, S Ott, . . . P Kearns, GS Taylor.
Nature 583:807-812 (2020). Middleton G, P Fletcher, S Popat, J Savage, Y Summers, A Greystoke, . . . L Billingham. .
Lancet Respir Med 8:895-904 (2020). Middleton G, K Brock, J Savage, R Mant, Y Summers, J Connibear, . . . L Billingham.